Aktiesnakken — Marts 2010
-
Pffff...
-
Finanshuset Nomura har nedjusteret sin anbefaling af Genmab til neutral"
fra "køb". -
target 85 ift 185 for en måned siden står der
-
(iflg. bloomberg)
-
de data var den kattelem de skulle bruge. Det er helt ufatteligt når ingen har den til over 16 kr i værdi
-
men ok.
-
lige en orintering. jeg vil live chatte fra ns CC her kl 15
-
Vi overvejer i øjeblikket, hvorvidt vi skal starte det, der hedder
et early access program, det vil sige på individuel basis tilbyde
patie -
enter behandling.... der er mange ting der taler for og imod... siger NEUR C
EO
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind